Login / Register
Search
About the Report:
The Japanese market for pharmaceuticals is amongst the largest in the world and, through many international networks opened to innovative products and services. In 2016, nearly one fifth of all drugs came from abroad, and foreign companies served about 70% of the particularly innovative market for biopharmaceuticals. This report titled "The Biopharmaceuticals sector in Japan: Government regulations, the competitive situation and how to find an entry point - A primer for European SMEs" aims to map out the current state of the biopharmaceuticals market in Japan. This report first highlights the Japanese healthcare system, and then outline the market access for biopharmaceutical products by pointing out the regulations system and main actors on this market. Finally, it presents various recommendations to EU companies for a successful market entry.
About the Experts:
Doctor Rolf Schmid is a biochemist, with post-doctoral stages in France and the USA. After 15 years of career in Germany's chemical industry and 7 years as director at a National Research Center, he was invited as a Director of Stuttgart University's Center of Bioprocess Engineering. Dr Schmid also founded Bio4Business, a consulting company in Stuttgart with a focus on Japan and China. Mr Schmid has promoted cooperation with Japanese companies and academia throughout his career.
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
